| Drug NDC: | 55714-4721 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Parasites |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Abrotanum, Aesculus Hipp., Allium Sativum, Arsenicum Alb., Artemisia, Baptisia, Cina, Cuprum Met., Filix Mas, Granatum, Ipecac, Lachesis, Lycopodium, Merc. Viv, Naphthalinum, Nat. Mur., Nux Vom., Pulsatilla, Ratanhia, Ruta, Sabadilla, Santoninum, Silicea, Spigelia Anth., Terebinthina, Teucrium Marum, Thymolum, Zingiber, Juglans Regia |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Newton Laboratories, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ANEMONE PULSATILLA - 20 [hp_X]/mL ARSENIC TRIOXIDE - 20 [hp_X]/mL ARTEMISIA ABROTANUM FLOWERING TOP - 20 [hp_X]/mL ARTEMISIA CINA PRE-FLOWERING TOP - 20 [hp_X]/mL ARTEMISIA VULGARIS ROOT - 20 [hp_X]/mL BAPTISIA TINCTORIA ROOT - 20 [hp_X]/mL COPPER - 20 [hp_X]/mL DRYOPTERIS FILIX-MAS ROOT - 20 [hp_X]/mL GARLIC - 20 [hp_X]/mL GINGER - 20 [hp_X]/mL Load more... HORSE CHESTNUT - 20 [hp_X]/mL IPECAC - 20 [hp_X]/mL JUGLANS REGIA LEAF - 11 [hp_X]/mL KRAMERIA LAPPACEA ROOT - 20 [hp_X]/mL LACHESIS MUTA VENOM - 20 [hp_X]/mL LYCOPODIUM CLAVATUM SPORE - 20 [hp_X]/mL MERCURY - 20 [hp_X]/mL NAPHTHALENE - 20 [hp_X]/mL PUNICA GRANATUM ROOT BARK - 20 [hp_X]/mL RUTA GRAVEOLENS FLOWERING TOP - 20 [hp_X]/mL SANTONIN - 20 [hp_X]/mL SCHOENOCAULON OFFICINALE SEED - 20 [hp_X]/mL SILICON DIOXIDE - 20 [hp_X]/mL SODIUM CHLORIDE - 20 [hp_X]/mL SPIGELIA ANTHELMIA - 20 [hp_X]/mL STRYCHNOS NUX-VOMICA SEED - 20 [hp_X]/mL TEUCRIUM MARUM - 20 [hp_X]/mL THYMOL - 20 [hp_X]/mL TURPENTINE OIL - 20 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 02 Sep, 2019 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 10 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Newton Laboratories, Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | M0005152 N0000175831 N0000008595 N0000008924 N0000175830 N0000185371 N0000175629 N0000184306 M0000728 M0006342 M0016962 N0000185375 M0008672 N0000185001 M0516536 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | I76KB35JEV S7V92P67HO QG07G580U0 28M1820ACT 32MP823R8S 5EF0HWI5WU 789U1901C5 C0ZK0RRF5X V1V998DC17 C5529G5JPQ Load more... 3C18L6RJAZ 62I3C8233L 85HKB87105 P29ZH1A35Z VSW71SS07I C88X29Y479 FXS1BY2PGL 2166IN72UN CLV24I3T1D N94C2U587S 1VL8J38ERO 6NAF1689IO ETJ7Z6XBU4 451W47IQ8X WYT05213GE 269XH13919 10464S0TAA 3J50XA376E C5H0QJ6V7F |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Copper-containing Intrauterine Device [EPC] Non-Standardized Food Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Decreased Embryonic Implantation [PE] Decreased Sperm Motility [PE] Inhibit Ovum Fertilization [PE] Increased Histamine Release [PE] Cell-mediated Immunity [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Copper [CS] Allergens [CS] Dietary Proteins [CS] Plant Proteins [CS] Food Additives [CS] Seed Storage Proteins [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Cell-mediated Immunity [PE] Copper [CS] Copper-containing Intrauterine Device [EPC] Decreased Embryonic Implantation [PE] Decreased Sperm Motility [PE] Dietary Proteins [CS] Food Additives [CS] Increased Histamine Release [PE] Increased IgG Production [PE] Inhibit Ovum Fertilization [PE] Non-Standardized Food Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] Plant Proteins [CS] Seed Storage Proteins [CS] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 55714-4721-1 | 30 mL in 1 BOTTLE, GLASS (55714-4721-1) | 02 Sep, 2019 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.